Fig 1.
MCL cell lines were treated with SRC-3 inhibitors.
A) SI-10 or B) SI-12 at various concentrations for 48 h and cell viability was determined using the resazurin assay C) Mino D) Jeko-1 growth inhibition with SI-10 (0–1 mM) for 6,12,24, or 48h.
Fig 2.
Mino parental and Mino venetoclax resistant cells were treated with various concentrations of venetoclax.
B) Jeko-1 parental and Jeko-1 ibrutinib resistant cells were treated with ibrutinib at various concentrations. C) Mino parental and resistant cells were treated with SI-10 and SI-12. D) Jeko-1 parental and resistant cells were treated with SI-10 and SI-12.
Fig 3.
SRC-3 treatment decreased tumor growth in a Jeko-1 ibrutinib resistant mouse model.
A) Volumes of tumors treated with SI-10 (50 mg/kg), ibrutinib (100mg/kg) or vehicle B) Weight of tumors treated with SI-10 (50 mg/kg), ibrutinib (100mg/kg) or vehicle before sacrificing C) The weight of each mouse was measured 3 times a week.
Fig 4.
SRC-3 treatment prolonged survival of A20-Balb/c mice.
Balb/c mice were injected with 1 x 106 A20 cells intravenously. Treatment started on day 7. A) Kaplan-Meier survival plot reflecting time to lethal tumor burden. Based on the log-rank test, there are significant differences between the treated group and the control (P < 0.05). B) Body weight of all groups were measured 5 days a week.
Fig 5.
SRC-3 inhibitor treatment in normal mice show little to no toxicity after treatment for 28 days.
A) Body weight of all groups were measured 5 days a week. B) Blood serum levels of clinical markers related to kidney and liver failure. Dotted lines represent upper and lower limits based on reference values. Data outliers were removed using the identify outlier function in Graphpad Prism with the ROUT method (Q = 1%).